DDInter105 DDInter200
A plasma alpha 2 glycoprotein that accounts for the major antithrombin activity of normal plasma and also inhibits several other enzymes. It is a member of the serpin superfamily.
Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals Inc., is prescribed as a venous thromboembolism (VTE) prophylactic for adult patients with moderate to severe restricted motility or with other risks for VTE . VTE can be manifested as deep vein thrombosis or pulmonary embolism and it is a leading cause of preventable death in hospitalized patients .
Betrixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Betrixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Amprenavir
Betrixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Berotralstat
Betrixaban {u} may lead to a major life threatening interaction when taken with {v} Iloprost
Betrixaban {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Betrixaban may cause a minor interaction that can limit clinical effects when taken with Clove
Betrixaban may cause a minor interaction that can limit clinical effects when taken with Turmeric
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir
Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat
Betrixaban may lead to a major life threatening interaction when taken with Iloprost
Betrixaban may lead to a major life threatening interaction when taken with Avapritinib